International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium–Glucose Cotransporter (SGLT) Inhibitors
Year: 2019
Type: article
Abstract: Sodium-glucose cotransporter (SGLT) inhibitors are new oral antidiabetes medications shown to effectively reduce glycated hemoglobin (A1C) and glycemic variability, blood pressure, and body weight without intrinsic properties to cause hypoglycemia in people with type 1 diabetes. However, recent studies, particularly in individuals with type 1 diabetes, have demonstrated increases in the absolute risk of diabetic ketoacidosis (DKA). Some cases presented with near-normal blood glucose levels or mild hyperglycemia, complicating the recognition/diagnosis of DKA and potentially delaying treatment. Several SGLT inhibitors are currently under review by the U.S. Food and Drug Administration and European regulatory agencies as adjuncts to insulin therapy in people with type 1 diabetes. Strategies must be developed and disseminated to the medical community to mitigate the associated DKA risk. This Consensus Report reviews current data regarding SGLT inhibitor use and provides recommendations to enhance the safety of SGLT inhibitors in people with type 1 diabetes.
Source: Diabetes Care
DOI: 10.2337/dc18-2316
Authors: Thomas Danne, Satish Garg, Anne L. Peters, John B. Buse, Chantal Mathieu, Jeremy H. Pettus, Charles M. Alexander, Tadej Battelino, F. Javier Ampudia-Blasco, Bruce W. Bode, Bertrand Cariou, Kelly L. Close, Paresh Dandona, Sanjoy Dutta, Ele Ferrannini, Spiros Fourlanos, George Grunberger, Simon R. Heller, Robert R. Henry, Martin J. Kurian, Jake A. Kushner, Tal Oron, Christopher G. Parkin, Thomas R. Pieber, Helena W. Rodbard, Desmond Schatz, Jay S. Skyler, William V. Tamborlane, Koutaro Yokote, Moshe Phillip
Institutions: Kinderkrankenhaus auf der Bult, University of Colorado Denver, University of Southern California, University of North Carolina at Chapel Hill, Universitair Ziekenhuis Leuven, KU Leuven, University of California San Diego, Advanced Resources International (United States), Gwynedd Council, Pharmacy Quality Alliance, University of Ljubljana, Ljubljana University Medical Centre, Hospital Clínico Universitario de Valencia, Atlanta Diabetes Associates, Inserm, Centre Hospitalier Universitaire de Nantes, Centre d'Investigation Clinique de Nantes, Institut du Thorax, University at Buffalo, State University of New York, Breakthrough T1D, Istituto di Fisiologia Clinica, National Research Council, The Royal Melbourne Hospital, Grunberger Diabetes Institute, University of Sheffield, Close Concerns (United States), Tel Aviv University, Schneider Children's Medical Center, Medical University of Graz, University of Florida Health, University of Florida, University of Miami, Yale University, Chiba University
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: green
Funders: Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, GlaxoSmithKline, Sanofi, Regeneron Pharmaceuticals, Les Laboratories Pierre Fabre, Intarcia Therapeutics, Insulet Corporation, MannKind Corporation, Dexcom, AstraZeneca HealthCare Foundation, National Institute for Health and Care Research, KU Leuven, Novo Nordisk, Servier, National Institutes of Health, National Center for Advancing Translational Sciences, Janssen Pharmaceuticals
OpenAlex ID: W2913123058